Nemesis of breast cancer
February 6th, 2010
As the birthplace of China’s cancer subjects, national breast cancer research led units, and has the largest breast cancer specialist and the first one in China as the main object of study of breast of breast cancer research Tianjin Cancer Hospital, now has accumulated 20000 more cases of breast cancer diagnosis and treatment experience in the system, integrated treatment for breast cancer to reach international advanced level.
Comprehensive Treatment
Comprehensive treatment is to surgery, chemotherapy, radiotherapy, immune, endocrine and traditional Chinese medicine treatment in a planned, purposeful combination of the treatment.
Why comprehensive treatment of breast cancer?
1, do not think that long lump in the breast will be on the bin down a mastectomy. Because breast cancer is a systemic disease, localized breast cancer, not only in growth, expansion and infiltration, but also through the lymph, lymphatic vessels to regional lymph node metastasis, as well as the transfer of blood to the body. Therefore, breast and regional lymph node resection completed only part of the treatment, there is no other adjuvant treatment measures, such as chemotherapy can not kill the cancer cells into the blood, once it is in an important organ implantation, would destroy the organ’s normal physiological function, resulting in death.
2, integrated treatment is good, the high survival rate
Tianjin Cancer Hospital from the age of 50-90 thousand cases of patients with treatment options and results we can see from the 50’s are mostly non-chemotherapy, radiotherapy and chemotherapy 90 years, endocrine, immune, genetic, and traditional Chinese medicine such as the integrated use of sequential therapy to 5 years survival rate than the 50 years survival rate increased 31%.
How to carry out a comprehensive treatment?
According to the specific circumstances of patients, the sick sooner or later, pathological inflammation type, number of axillary lymph node metastasis, and receptor status, etc. to adopt a different combined treatment programs. Early breast cancer (ductal carcinoma in situ and early invasive), very low risk of recurrence from time of radiotherapy. Medium-term postoperative chemotherapy (including 1.5cm above the risk of recurrence in the medium). Middle and Late (axillary lymph node metastasis) should be in the preoperative, intraoperative, postoperative radiotherapy and chemotherapy and other adjuvant therapy.